Related Experiment Video
Updated: May 8, 2026
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Orally inhaled dihydroergotamine: a review
1Cleveland Clinic, Cleveland, OH, USA.
Headache
|September 13, 2013
Summary
Orally inhalable dihydroergotamine (iDHE) offers a user-friendly migraine treatment. This dihydroergotamine (DHE) formulation effectively manages severe migraine attacks, even when taken later, with a favorable safety profile.
Area of Science:
- Pharmacology
- Neurology
- Drug Delivery Systems
Background:
- Dihydroergotamine (DHE) is an established migraine medication with a complex receptor profile.
- Its efficacy is linked to central nervous system penetration and sustained receptor binding.
- Existing DHE formulations face challenges like first-pass metabolism and gastrointestinal absorption issues during migraines.
Purpose of the Study:
- To evaluate the efficacy and safety of orally inhalable dihydroergotamine (iDHE) for acute migraine treatment.
- To assess the pharmacokinetic advantages of the iDHE formulation compared to other DHE routes.
- To determine the clinical utility of iDHE in specific migraine subtypes and challenging scenarios.
Main Methods:
- Phase 3 clinical trial and safety extension trial of orally inhalable dihydroergotamine (iDHE).
- Assessment of pharmacokinetics, including maximal serum concentration and receptor binding.
- Evaluation of efficacy in treating various migraine presentations and patient-reported outcomes like nausea and taste.
Main Results:
- Orally inhalable dihydroergotamine (iDHE) demonstrated a favorable pharmacokinetic profile with lower Cmax than IV DHE, potentially reducing nausea.
- The inhalable formulation bypasses the GI tract, avoiding first-pass metabolism and absorption issues.
- No serious drug-related adverse events were reported; nausea and taste were the most common side effects.
Conclusions:
- Orally inhalable dihydroergotamine (iDHE) represents a promising, user-friendly formulation of DHE for acute migraine treatment.
- Its pharmacokinetic and administration advantages make it effective for various migraine types, including those with nausea or occurring later in the attack.
- iDHE offers a valuable option for patients needing effective migraine relief, with a generally good safety profile, though contraindications for vascular disease apply.
Related Concept Videos
01:22Drug Delivery: Miscellaneous Routes
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
01:24Cholinergic Antagonists: Pharmacokinetics
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
01:18Drug Delivery: Enteral Route
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
Drugs in...
Drugs in...
01:18Additional Routes of Drug Administration
Choosing the appropriate route of drug administration is significantly influenced by two key factors: the therapeutic objectives and the inherent properties of the drug being used.
Administering drugs via inhalation allows for the direct delivery of gaseous, volatile substances or droplets to different parts of the respiratory tract. One of the advantages of the inhalation route is the rapid absorption of drugs into the circulatory system, which is possible because of the large surface area of...
Administering drugs via inhalation allows for the direct delivery of gaseous, volatile substances or droplets to different parts of the respiratory tract. One of the advantages of the inhalation route is the rapid absorption of drugs into the circulatory system, which is possible because of the large surface area of...
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:28Adrenergic Agonists: Mixed-Action Agents
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...